To the Editor.
—We are writing in response to the article on the use of interferon for treating condyloma1 and the accompanying editorial,2 which appeared in the Jan 22/29 issue of JAMA.We are concerned about the adequacy of the evaluation given to female patients before the start of therapy. In our experience, 68% of patients referred with vulval condyloma had biopsyproved cervical and vaginal pathology.3 In the absence of colposcopic evaluation, how are we to be sure that the patients treated in this study did not indeed have vaginal and cervical lesions? If we accept this possibility, then the results are called into question. Did the patient who had a vulval response also have responsive internal lesions? Or are the patients who failed to respond those patients in whom vaginal and cervical lesions were present and not treated? We are particularly concerned since in our experience
William J. Mann, Bruce Patsner, Eva Chalas. Interferon and Genital Condylomata. JAMA. 1988;259(20):2999. doi:10.1001/jama.1988.03720200021024